Étude du ZMA001 intraveineux chez des sujets sains
Une étude de phase 1 randomisée, en double aveugle, contrôlée par placebo et à dose unique croissante pour évaluer l'innocuité, la tolérabilité et la pharmacocinétique du ZMA001 intraveineux chez des sujets sains
Background:
A number of diseases can cause a type of lung injury called pulmonary arterial hypertension (PAH). Most people who develop PAH do not survive more than a few years. A new study drug (ZMA001) may help. ZMA001 is a monoclonal antibody. This type of drug consists of proteins, made in a facility, that are very similar to proteins in a human body. But before giving ZMA001 to people sick with PAH, researchers want to find out how the drug affects healthy people.
Objective:
To test a drug (ZMA001) in healthy volunteers.
Eligibility:
Healthy adults aged 18 to 60 years.
Design:
Participants will be screened. They will have a physical exam with blood tests. They will have a urine test for drug use. They will have a test of their heart function.
Participants will come to the clinic for 1 inpatient visit of up to 48 hours.
ZMA001 is a liquid administered through a tube attached to a needle inserted into a vein in the arm. Participants will receive this drug only once, during their inpatient stay. Some participants will receive the drug; others will receive a placebo in Cohort 1 only. A placebo is a treatment that looks just like the real drug but contains no medicine. Participants will not know which treatment they are getting in Cohort 1. Cohorts 2-4 will receive a single dose of the study drug, administered through a tube attached to a needle inserted into a vein in the arm.
After a screening visit, participants will have 1 inpatient visit and up to 8 outpatient visits over 16 weeks after receiving the treatment. Blood draws and other tests will be repeated. Each outpatient visit is approximately 2 hours long.
This study is the first time ZMA001 will be administered to people.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
Study Description:
ZMA001 is a fully human, monoclonal antibody (IgG1) that inhibits migration of activated monocytes and macrophages and reduces pulmonary vascular remodeling and pulmonary artery pressure in pre-clinical rodent models of pulmonary arterial hypertension (PAH). The current first-in-human, single ascending-dose study will determine the safety, tolerability, and pharmacokinetics of intravenous ZMA001 in healthy subjects.
Objectives:
Primary Objective: Safety and tolerability of ZMA001 in healthy subjects
Secondary Objectives: Determine the pharmacokinetics of ZMA001 in healthy subjects following a single, intravenous dose
Endpoints:
Primary Endpoint: The number of all-cause, treatment-emergent adverse events, grade 1 and above (following CTCAE v5.0 criteria) through day 113
Secondary Endpoints: For each ZMA001 dose level (1.5, 0.25, 0.50, and 1.0 mg/kg), the following will be determined [Timeframe: Pre-infusion, end of infusion, 2, 4, 8, 12, 24, and 48h; Days 8, 15, 22, 29, 57, 85 and 113]:
- Time to peak drug concentration (Tmax)
- Peak drug concentration (Cmax)
- Area under the drug concentration-time curve (AUC)
- Elimination half-life
Type d'étude
Type d'étude
Inscription (Réel)
Inscription
Phase
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
Maryland
-
Bethesda, Maryland, États-Unis, 20892
- National Institutes of Health Clinical Center
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
- INCLUSION CRITERIA:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
-
Stated willingness to comply with all study procedures and availability for the duration of the study
-
Male* or female, aged 18 to 60 years, inclusive
-
In good general health as evidenced by medical history
-
Females of childbearing potential agree to use an accepted method of contraception (see below) throughout study participation and for 120 days after study drug infusion.
-
Males sexually active with a female partner must agree to use a condom with spermicide for 120 days after study drug infusion or be surgically sterile for at least 90 days before screening. Males must also agree to not donate sperm for 120 days after study drug administration.
-
Agreement to adhere to Lifestyle Considerations throughout study duration
-
Ability of subject to understand and the willingness to sign a written informed consent document.
- Enrollment of healthy male subjects will be limited to no more than 14 out of the total study cohort of 32 in order to ensure an adequate representation of female subjects.
Accepted methods of contraception for females of childbearing potential:
- Use of an implanted or intrauterine hormonal device for at least 30 consecutive days before study drug infusion
- Use of oral, patch or injectable contraceptives or a vaginal hormonal device for at least 30 consecutive days before study drug infusion
- Use of a non-hormonal intrauterine device for at least 30 consecutive days before study drug infusion
- Two barrier methods such as a diaphragm with spermicide or a condom with spermicide
EXCLUSION CRITERIA:
An individual who meets any of the following criteria prior to informed consent will be excluded from participation in this study:
- Pregnancy or lactation. Females of childbearing potential must have a negative serum Beta-human chorionic gonadotropin test no more than 48 hours from study drug infusion.
- A history of human immunodeficiency virus (HIV) infection.
- History of severe drug or excipient allergy or hypersensitivity
- Known allergy to any of the components of the investigational drug or placebo
- Recent infection or febrile illness within the past 14 days
- Treatment with another investigational drug within the past 30 days or 5 half-lives, whichever is longer
- Any vaccination within the past 4 weeks or receipt of a live-attenuated vaccine within the past 6 months
- Use of tobacco products within the past 3 months
- Illicit drug use (e.g. cocaine, opioids, methamphetamine, PCP) within the past 6 months or positive urine drug screen at Screening Visit
- Marijuana (cannabis) use within the past 30 days or positive urine drug screen at Screening Visit
- History of alcohol abuse within the past 2 years
- Current clinically significant medical illness that is uncontrolled despite appropriate medical treatment including (but not limited to) hematologic, oncologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, infectious, hepatic, dermatologic, psychiatric, neurologic, autoimmune or allergic disease
- Body mass index less than 17 or greater than 32 kg/m^2
- Clinically significant abnormal results on clinical blood testing completed at the Screening Visit
- Electrocardiographic evidence of clinically relevant heart disease
- Diabetes mellitus requiring medical treatment
- Received another monoclonal antibody in the past 30 days
- Use of herbal supplements, or similar products within the past 2 weeks
- Blood donation equal to or above 500 mL within 2 months prior to dosing.
- Any other finding that, in the judgment of the Investigator, would increase the risk of having an adverse outcome from participating in the study.
Justification to exclude minors: Given that the vast majority of patients with PAH are >18 years of age and the fact that this is a first in human study, the risks of including children/minors (ie. subjects < 18 yrs of age) are not justified given the limited potential benefits of including these subjects.
Justification to exclude adults >60 years old: Subjects > 60 years of age are more likely to have comorbid medical conditions that could place them at increased risk of participation.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Non randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Comparateur placebo: Placebo Cohort 1 (1.5 mg/kg/dose) only
Placebo for ZMA001 is supplied in a single-use 10 mL glass vial. Each vial contains 30 mg/mL of sucrose.Placebo drug is manufactured using the same ingredients as active drug (20 mM histidine-HCl buffer [pH 5.6], 30 mg/mL sucrose, 0.070 w/v% polysorbate 80) excluding ZMA001 antibody and is packed in the same vial. |
30mg/ml Sucrose |
|
Expérimental: ZMA001 (BC-NKA-20008)
ZMA001 is a fully human, monoclonal antibody (IgG1) that inhibits migration of activated monocytes and macrophages and reduces pulmonary vascular remodeling and pulmonary artery pressure in pre-clinical rodent models of pulmonary arterial hypertension (PAH). |
ZMA001 is a fully human, monoclonal antibody (IgG1) that inhibits migration of activated monocytes and macrophages and reduces pulmonary vascular remodeling and pulmonary artery pressure in pre-clinical rodent models of pulmonary arterial hypertension (PAH). |
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Safety and tolerability of ZMA001 in healthy subjects
Délai: day 113
|
The number of all-cause, treatment-emergent adverse events, grade 1 and above (following CTCAE v5.0 criteria) through day 113 |
day 113
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Determine the pharmacokinetics of ZMA001 in healthy subjects following a single, intravenous dose.
Délai: Pre-infusion, end of infusion, 2, 4, 8, 12, 24, and 48h; Days 8, 15, 22, 29, 57, 85 and 113
|
For each ZMA001 dose level (1.5, 0.25, 0.50, and 1.0 mg/kg), the following will be determined.3. Area under the drug concentration-time curve(AUC) |
Pre-infusion, end of infusion, 2, 4, 8, 12, 24, and 48h; Days 8, 15, 22, 29, 57, 85 and 113
|
|
Determine the pharmacokinetics of ZMA001 in healthy subjects following a single, intravenous dose.
Délai: Pre-infusion, end of infusion, 2, 4, 8, 12, 24, and 48h; Days 8, 15, 22, 29, 57, 85 and 113
|
For each ZMA001 dose level (1.5, 0.25, 0.50, and 1.0 mg/kg), the following will be determined.2. Peak drug concentration (Cmax) |
Pre-infusion, end of infusion, 2, 4, 8, 12, 24, and 48h; Days 8, 15, 22, 29, 57, 85 and 113
|
|
Determine the pharmacokinetics of ZMA001 in healthy subjects following a single, intravenous dose.
Délai: Pre-infusion, end of infusion, 2, 4, 8, 12, 24, and 48h; Days 8, 15, 22, 29, 57, 85 and 113
|
For each ZMA001 dose level (1.5, 0.25, 0.50, and 1.0 mg/kg), the following will be determined.1. Time to peak drug concentration (Tmax) |
Pre-infusion, end of infusion, 2, 4, 8, 12, 24, and 48h; Days 8, 15, 22, 29, 57, 85 and 113
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Collaborateurs
Collaborateurs
Les enquêteurs
Les enquêteurs
- Chercheur principal: Jason M Elinoff, M.D., National Heart, Lung, and Blood Institute (NHLBI)
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- 10001522
- 001522-H
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
All IPD that underlie results in a publication.
Délai de partage IPD
Data will be made available at the time of associated publication and the duration of availability is expected to be indefinite but will ultimately be determined by the NHLBI.@@@@@@
Critères d'accès au partage IPD
Data will be shared through the NHLBI BioData Catalyst, which is a controlled access repository.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .